Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Common Equity (2016 - 2026)

Ocular Therapeutix has reported Common Equity over the past 14 years, most recently at $581.6 million for Q1 2026.

  • For Q1 2026, Common Equity rose 118.69% year-over-year to $581.6 million; the TTM value through Mar 2026 reached $581.6 million, up 118.69%, while the annual FY2025 figure was $654.3 million, 107.49% up from the prior year.
  • Common Equity for Q1 2026 was $581.6 million at Ocular Therapeutix, down from $654.3 million in the prior quarter.
  • Over five years, Common Equity peaked at $654.3 million in Q4 2025 and troughed at $3.1 million in Q2 2023.
  • A 5-year average of $226.9 million and a median of $258.2 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: plummeted 95.31% in 2023 and later surged 12135.02% in 2024.
  • Year by year, Common Equity stood at $35.4 million in 2022, then skyrocketed by 157.59% to $91.1 million in 2023, then surged by 246.03% to $315.3 million in 2024, then skyrocketed by 107.49% to $654.3 million in 2025, then decreased by 11.12% to $581.6 million in 2026.
  • Business Quant data shows Common Equity for OCUL at $581.6 million in Q1 2026, $654.3 million in Q4 2025, and $258.2 million in Q3 2025.